Hormone receptor positive HER2 negative breast cancer+1
Not recruitingStudy on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors
Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors
- Disease:Hormone receptor positive HER2 negative breast cancerPIK3CA-activated mutation
- Substances:Alpelisib
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Alpelisib
- Sponsor:BOOG Study Center B.V.





